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http://dx.doi.org/1(HF). The presence and extent of myocardial ﬁbrosis assessed by cardiac magnetic resonance
(CMR) and high levels of cTnT predict poor prognosis in various cardiomyopathies. However,
the association between myocardial ﬁbrosis and transcardiac cTnT release has not been eval-
uated. This study investigated the correlation between myocardial ﬁbrosis and transcardiac
cTnT release from nonischemic failing myocardium. Serum cTnT levels were measured in
aortic root (Ao) and coronary sinus (CS) using highly sensitive assay (detection limit>5 ng/L) in
74 nonischemic patients with HF who underwent CMR. Transcardiac cTnT release (DcTnT
[CS-Ao]) represented the difference between CS and Ao-cTnT levels. Myocardial ﬁbrosis was
quantiﬁed by late gadolinium enhancement (LGE) volume and %LGE on CMR. cTnT was
detectable in 65 patients (88%), and DcTnT (CS-Ao) levels were available (DcTnT [CS-Ao]
>0 ng/L) in 60 patients (81%). LGE was observed in 42 patients (57%), and DcTnT (CS-Ao)
levelswere available in 41LGE-positive patients (98%). In patientswith available cTnT release,
DcTnT (CS-Ao) levels were signiﬁcantly higher in LGE-positive patients than those in LGE-
negative patients (4.3 [2.2L5.5] vs 1.5 [0.9L2.6] ng/L; p[ 0.001). Log (DcTnT [CS-Ao]) levels
were correlated with LGE volume (r[ 0.460, p[ 0.003) and %LGE (r[ 0.356, p[ 0.03). In
conclusion, the amount of transcardiac cTnT release was higher in LGE-positive patients than
LGE-negative patients and correlatedwith the extent of LGE in nonischemic patients with HF.
These results suggested that ongoing myocardial damage correlates with the presence and
extent of myocardial ﬁbrosis.  2014 The Authors. Published by Elsevier Inc.
(Am J Cardiol 2014;113:1697e1704)Open access under CC BY-NC-ND license.Persistent and modest elevation of circulating cardiac
troponin is frequently observed and represents ongoing sub-
clinical myocardial damage in patients with heart failure (HF)
regardless of overt coronary artery disease.1 High levels of
cardiac troponin predict poor prognosis in patients with HF
and several nonischemic cardiomyopathies.2,3 Myocardial
ﬁbrosis is a common feature of wide variety of cardiomyop-
athies and is thought to contribute to cardiac dysfunction,f aCardiovascular Medicine and bDiagnostic Radiology,
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Open access under CC ventricular tachyarrhythmia, sudden cardiac death, and pro-
gression of HF.4,5 Cardiac magnetic resonance (CMR) im-
agingwith the late gadolinium enhancement (LGE) technique
allows the detection of myocardial ﬁbrosis.6 It has been
reported that the presence and extent of CMR-LGE are a
useful predictor of sudden cardiac death and adverse outcome
in several nonischemic cardiomyopathies.7e10 It has been
speculated that persistent troponinemia, representing ongoing
subclinical myocardial damage, represents progressive
myocardial ﬁbrosis and contributes to the progression of
HF.11 However, this concept has not been fully demonstrated
in patients with HF in the clinical situation. In this study, we
directly measured transcardiac cardiac troponin T (cTnT)
release into the coronary circulation using the highly sensitive
cTnT (hs-cTnT) assay and investigated the correlation be-
tween the presence and the extent of myocardial ﬁbrosis
assessed by CMR-LGE and transcardiac cTnT release in
nonischemic patients with HF.
Methods
The study subjects were 74 consecutive patients with
nonischemic HF who underwent both cardiac catheterizationwww.ajconline.orgBY-NC-ND license.
Figure 1. Representative images used for quantitative analysis of CMR-LGE. (A) The CMR short-axis LGE images from a patient with dilated phase of
hypertrophic cardiomyopathy. (B) Pink area represents hyperenhanced myocardium resembling LGE, deﬁned as 6 SDs above the mean signal intensity of
normal remote myocardium.
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and September 2013 at the Kumamoto University Hospital.
The interval of the performance of cardiac catheterization and
CMR was within 3 months, and the mean interval of the 2
procedures was 10 12 days. Eligible patients were 20 years
or older whomet the criteria for the diagnosis of HF set by the
American College of Cardiology/American Heart Associa-
tion Stage B or C classiﬁcation.12 All patients were clinically
stable and under optimal medical therapy for HF,13 including
stable doses of an angiotensin-converting enzyme inhibitor
or angiotensin II receptor blocker, a b blocker, and an aldo-
sterone blocker if not contraindicated. The following exclu-
sion criteria were applied during patient selection:
decompensated HF, ischemic HF, acute coronary syndrome,
signiﬁcant coronary artery stenosis (>50%), renal insufﬁ-
ciency with estimated glomerular ﬁltration rate <30 ml/min/
1.73 m2, myocarditis, muscular dystrophy, polymyositis,
patients with cardiovascular implantable electronic device,
and chronic inﬂammatory disease. Written informed consent
was obtained from each patient before cardiac catheteriza-
tion, and the study was approved by the Human Ethics
Committee of our institution.
A 5Fr or 6Fr arterial cannula was placed in the radial or
femoral artery, and a 6Fr venous sheath was placed in the
right femoral vein. A coronary sinus (CS) catheter (Goodtec,
Gifu, Japan) was advanced to the CS from the venous sheath,
and its position was conﬁrmed by ﬂuoroscopy with contrast
media. Blood samples were collected simultaneously from
the aortic root (Ao) and CS. Right heart catheterization was
performed using a 6F Swan-Ganz catheter (Fukuda Denshi,
Tokyo, Japan) to measure hemodynamic parameters. Coro-
nary angiography was then performed after administration of
intracoronary isosorbidedinitrate to conﬁrm the absence of
signiﬁcant epicardial coronary artery stenosis.
The serum and plasma samples were frozen at 80C
until analysis. Serum cTnT levels were measured using theElecsys 2010 Troponin T hs kit (Roche Diagnostics, Indi-
anapolis, Indiana). The lower limit of detection is 5 ng/L
with a reported ninety-ninth percentile value in apparently
healthy patients of 13.5 ng/L. At the ninety-ninth percentile
value, the coefﬁcient of variation is 9% by Elecsys 2010
analyzer.14 Plasma B-type natriuretic peptide (BNP) levels
were measured using the MI02 Shionogi BNP kit (Shionogi,
Osaka, Japan). Transcardiac cTnT and BNP releases from
the myocardium were calculated as the differences between
CS and Ao levels of cTnT (DcTnT [CS-Ao]) and BNP
(DBNP [CS-Ao]), respectively.
CMR was performed on a 3.0 T MR instrument (Achieva
3.0 T X-series or Achieva 3.0 T X-series TX; Philips
Medicals Systems, Best, The Netherlands). The patients
were scanned in the supine position using a dedicated 6- and
32-channel cardiac torso coil, respectively, between January
2007 and April 2010 and between May 2010 and September
2013. Double-angulated scout images were obtained for
planning cardiac axis views. In all patients, images were
acquired using T1- and T2-weighted black blood, electro-
cardiogram-gated cine imaging by a segmented steady-state
free-precession sequence in the 3 long cardiac axes, and
LGE imaging. Approximately 10 minutes after the injection
of 0.1 mmol/kg of a gadolinium-based contrast agent
(Magnevist; Bayer Healthcare, Germany), we acquired 2-
dimension inversion-recovery sequences that covered the
left ventricle from the base to the apex. The imaging pa-
rameters were repetition time/echo time, 4.5/2.2 ms; inver-
sion time, 250 to 350 ms; ﬂip angle, 15; ﬁeld of view,
380  304 mm; acquisition matrix size, 1.19  1.94 mm for
6-channel coil and 0.95  1.13 mm for 32-channel coil;
reconstruction matrix size, 0.74  0.75 mm; slice thickness,
8.0 mm; bandwidth, 428.9 Hz per pixel; sensitivity encod-
ing factor, 2.
CMR data were analyzed using commercially available
postprocessing software (AZE Virtual Place; AZE, Tokyo,
Table 1
Demographic and clinical characteristics of participating patients
Variable n ¼ 74
Age (yrs) 60  15
Men 48 (65)
Body mass index (kg/m2) 23.9  4.3
New York Heart Association functional class
(I/II/III/IV)
21/45/8/0
Hypertension* 40 (54)
Dyslipidemia† 36 (49)
Diabetes mellitus 12 (16)
Atrial ﬁbrillation 22 (30)
Previous HF hospitalization 15 (20)
Hemodynamic status
Cardiac index (L/min/m2) 2.37  0.61
PCWP (mm Hg) 11.5  4.7
LVEDP (mm Hg) 11.4  7.0
Laboratory and imaging ﬁndings
cTnT level; detectablez 65 (88)
(cTnT level in CS)  (cTnT level in Ao); availablex 60 (81)
cTnT level in Ao (ng/L; n ¼ 65) 12.4 (9.7e20.7)
(cTnT level in CS)  (cTnT level in Ao)
(ng/L; n ¼ 60)
3.2 (1.5e5.0)
BNP level in Ao (pg/ml) 107 (52e251)
(BNP level in CS)  (BNP level in Ao) (pg/ml) 223 (89e361)
Hemoglobin (g/dl) 14.2  1.9
Hemoglobin A1c (%) 6.0  0.9
Estimated glomerular ﬁltration rate
(ml/min/1.73 m2)
67  17
High-sensitivity C-reactive protein (mg/dl) 0.08 (0.03e0.23)
Left ventricular ejection fraction (%) 42.3  12.5
LGE; positive 42 (57)
Etiology of HF
Dilated cardiomyopathy 38 (51)
Hypertrophic cardiomyopathy 12 (16)
Hypertensive cardiomyopathy{ 8 (11)
Othersk 16 (22)
Medications
Loop diuretics 31 (42)
b blockers 59 (80)
Angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers
61 (82)
Aldosterone antagonists 31 (42)
Digitalis 8 (11)
Values are presented as mean  SD, median (interquartile range), and n
(%).
LVEDP ¼ left ventricular end-diastolic pressure; PCWP ¼ pulmonary
capillary wedge pressure.
* Deﬁned as treated with antihypertensive drugs or blood pressure 140/
90 mm Hg.
† Deﬁned as treated with lipid-lowering drugs or low-density cholesterol
140 mg/dl and/or serum triglyceride 150 mg/dl and/or high-density
cholesterol <40 mg/dl.
z Serum cTnT levels >5 ng/L (detection limit of hs-cTnT assay).
x [(cTnT level in CS)  (cTnT level in Ao)] >0 ng/L in patients with
detectable cTnT levels.
{ Deﬁned as a previous history of long-standing hypertension and pres-
ence of left ventricular hypertrophy (left ventricular mass index 101 g/m2
in women and 117 g/m2 in men) in the absence of a cause other than
hypertension.
k Other etiologies included the followings: cardiac amyloidosis (n ¼ 4),
tachycardia-induced cardiomyopathy (n¼ 3), valvular heart disease (n¼ 2),
diabetic cardiomyopathy (n ¼ 2), left ventricular noncompaction (n ¼ 2),
unclassiﬁed cardiomyopathy (n ¼ 2), and mitochondrial cardiomyopathy
(n ¼ 1).
Heart Failure/LGE Correlates With cTnT Release in HF 1699Japan). The endocardial and epicardial borders of the
myocardium were traced manually on each short-axis slice.
Left ventricular volumes were calculated by subtracting
endocardial volume from epicardial volume at end-diastole.
A board-certiﬁed cardiovascular radiologist blinded to the
results of biomarker analysis independently determined the
dichotomous presence or absence of LGE in the left
ventricle. Hyperenhanced myocardial voxels resembling
LGE were deﬁned as signal intensity higher than the 6 SDs
above the mean intensity of the region of interest, which was
placed over an area of the myocardium evaluated as
normal.8,15,16 Quantitative measurement of the extent of
myocardial ﬁbrosis represented the sum of the hyper
enhanced myocardial voxels from each of the short-axis
images (Figure 1) by 2 cardiologists blinded to the clinical
data. %LGE was expressed as the percentage of LGE vol-
ume to total left ventricular volume.
Normally distributed parameters are presented as mean 
SD, whereas data of variables with skewed distribution are
expressed as medians with interquartile ranges. Differences
between groups were examined by the Student t or the
Mann-Whitney U test for unpaired data. Categorical pa-
rameters are presented as numbers (percentage) and
compared by the chi-square or Fisher’s exact test as
appropriate. Parameters with a skewed distribution were
transformed logarithmically before Pearson’s correlation to
fulﬁll the conditions required for the types of analysis.
Univariate logistic regression analysis was performed to
identify signiﬁcant parameters related to the positive LGE
ﬁnding. Then, multivariate logistic regression analysis was
performed using the forced inclusion model. The Hosmer-
Lemeshow statistic was applied to assess model calibration.
Linear relations between the extent of LGE and key vari-
ables were analyzed by univariate analysis. A 2-tailed value
of p <0.05 was considered statistically signiﬁcant. All sta-
tistical analyses were performed with the SPSS software,
version 19 (SPSS Inc., Chicago, Illinois).
Results
Table 1 lists the baseline characteristics of the study
patients. The serum cTnT levels were detectable (hs-cTnT
>5 ng/L) in 65 patients with HF (88%). Of these, DcTnT
(CS-Ao) levels were available (DcTnT [CS-Ao] >0 ng/L) in
60 patients (81%). cTnT levels in Ao (Ao-cTnT), repre-
senting the circulating cTnT levels, correlated positively
with DcTnT (CS-Ao) levels (r ¼ 0.517, p <0.001).
Furthermore, DBNP (CS-Ao) levels were available in all
study patients and were signiﬁcantly higher in patients with
available DcTnT (CS-Ao) levels than those without (249
[113e385] vs 124 [35e225] pg/ml, p ¼ 0.01).
LGE was observed in 42 patients (57%; Table1). Table 2
compares the baseline characteristics of LGE-positive and
LGE-negative patients. The percentages of patients with
available DcTnT (CS-Ao) levels and those with Ao-cTnT
of >13.5 ng/L were signiﬁcantly higher in LGE-positive
patients than in LGE-negative patients (98% vs 59%,
p <0.001; 55% vs 21%, p ¼ 0.004, respectively). Among
patients with available DcTnT (CS-Ao) levels, DcTnT
(CS-Ao) levels were also signiﬁcantly higher in LGE-
positive patients than in LGE-negative patients (4.3
Table 2
Clinical characteristics of late gadolinium enhancement (LGE)-positive and LGE-negative study patients
Variable LGE Positive (n ¼ 42) LGE Negative (n ¼ 32) p Value
Age (yrs) 61  16 59  14 0.66
Men 29 (69) 19 (59) 0.39
Body mass index (kg/m2) 23.9  4.1 23.8  4.6 0.85
New York Heart Association functional class (I/II/III/IV) 12/23/7/0 9/22/1/0
Hypertension 24 (57) 16 (50) 0.54
Dyslipidemia 20 (48) 16 (50) 0.84
Diabetes mellitus 6 (14) 6 (19) 0.61
Atrial ﬁbrillation 11 (26) 11 (34) 0.35
Previous HF hospitalization 9 (21) 6 (19) 0.78
Hemodynamic status
Cardiac index (L/min/m2) 2.38  0.69 2.36  0.52 0.89
PCWP (mm Hg) 12.9  4.8 9.8  4.0 0.004
LVEDP (mm Hg) 12.5  8.1 10.0  4.9 0.10
Laboratory and imaging ﬁndings
cTnT level in Ao* (ng/L) 13.9 (10.5e21.7) 10.8 (8.4e16.0) 0.047
cTnT level in Ao >13.5 ng/L 23 (55) 7 (21) 0.004
(cTnT level in CS)  (cTnT level in Ao); available 41 (98) 19 (59) <0.001
BNP level in Ao (pg/ml) 133 (62e338) 82 (24e151) 0.02
(BNP level in CS)  (BNP level in Ao) (pg/ml) 270 (158e440) 137 (41e290) 0.002
Hemoglobin (g/dl) 14.6  1.8 13.8  1.9 0.052
Hemoglobin A1c (%) 6.0  0.8 6.1  1.1 0.78
Estimated glomerular ﬁltration rate (ml/min/1.73 m2) 65  17 69  18 0.37
High-sensitivity C-reactive protein (mg/dl) 0.10 (0.06e0.20) 0.05 (0.03e0.25) 0.17
Left ventricular ejection fraction (%) 43.5  13.5 40.8  11.1 0.36
Etiology of HF
Dilated cardiomyopathy 16 (38) 22 (69)
Hypertrophic cardiomyopathy 12 (29) 0 (0)
Hypertensive cardiomyopathy 4 (10) 4 (13)
Others 14 (33) 6 (19)
Medications
Loop diuretics 17 (41) 14 (44) 0.77
b blockers 32 (76) 27 (84) 0.39
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers 33 (79) 28 (88) 0.32
Aldosterone antagonists 19 (45) 12 (38) 0.50
Digitalis 3 (7) 5 (16) 0.28
Values are presented as mean  SD, median (interquartile range), and n (%).
LVEDP ¼ left ventricular end-diastolic pressure; PCWP ¼ pulmonary capillary wedge pressure.
* cTnT level in Ao was detected in every blood sample of LGE-positive patients and in 23 LGE-negative patients.
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Univariate and multivariate logistic regression analyses
were performed to identify the independent parameters of
LGE-positive ﬁnding in the study patients. Univariate
analysis identiﬁed pulmonary capillary wedge pressure,
Ao-cTnT >13.5 ng/L, availability of DcTnT (CS-Ao)
levels, BNP levels in Ao (Ao-BNP), and DBNP (CS-Ao)
levels correlated signiﬁcantly with LGE-positive ﬁnding.
Multivariate logistic regression analysis using forced
inclusion model with age, gender, pulmonary capillary
wedge pressure, Ao-cTnT >13.5 ng/L, availability of
DcTnT (CS-Ao) levels, and DBNP (CS-Ao) levels identi-
ﬁed pulmonary capillary wedge pressure (odds ratio 1.19,
95% conﬁdence interval 1.02 to 1.40, p ¼ 0.03) and
availability of DcTnT (CS-Ao) levels (odds ratio 25.00,
95% conﬁdence interval 2.56 to 243.96, p ¼ 0.006) as in-
dependent and signiﬁcant correlates with LGE-positive
ﬁnding (Table 3).
Among the 42 LGE-positive patients, DcTnT (CS-Ao)
level was not available in 1 patient, and the extent of LGEcould not be evaluated in 2 patients due to insufﬁcient image
quality of LGE-CMR images for quantitative analysis.
Therefore, data of 39 patients were analyzed for the associa-
tion between the extent of LGE and the transcardiac cTnT
release. The total left ventricular volumewas 135.7 37.7ml,
whereas LGE volume and %LGE were 17.2  18.0 ml and
12.2  10.8%, respectively. Log (DcTnT [CS-Ao]) levels
correlated positivelywith LGE volume (r¼ 0.460, p¼ 0.003)
and %LGE (r ¼ 0.356, p ¼ 0.03; Table 4; Figure 3). Left
ventricular end-diastolic pressure, log (Ao-cTnT) levels, and
log (Ao-BNP) levels also correlated positively with LGE
volume and %LGE, respectively. Furthermore, log (DBNP
[CS-Ao]) levels correlated positively with %LGE.
Discussion
This is the ﬁrst report that investigated the association
between the transcardiac cTnT release and the presence and
extent of myocardial ﬁbrosis assessed by LGE-CMR in
nonischemic patients with HF. The major ﬁndings of the
Figure 2. Comparison of transcardiac cTnT release in patients with or
without LGE. DcTnT (CS-Ao) levels were signiﬁcantly higher in LGE-
positive patients than those in LGE-negative patients among patients in
whom DcTnT (CS-Ao) levels were available. Data are presented as median
and interquartile range. DcTnT (CS-Ao) ¼ (cTnT level in CS)  (cTnT
level in Ao).
Heart Failure/LGE Correlates With cTnT Release in HF 1701present study were as follows: (1) DcTnT (CS-Ao) levels
were more frequently available and signiﬁcantly higher in
LGE-positive patients compared with LGE-negative pa-
tients, (2) availability of DcTnT (CS-Ao) levels was an in-
dependent and signiﬁcant correlate with LGE-positive
ﬁnding, and (3) DcTnT (CS-Ao) levels correlated positively
with LGE volume and %LGE. Together, these ﬁndings
indicate the amount of transcardiac cTnT release was
increased in patients with myocardial ﬁbrosis, and high
transcardiac cTnT release represents the presence and extent
of myocardial ﬁbrosis in patients with nonischemic HF.
The exact mechanism responsible for troponin release
from the myocardium remains speculative in patients with
HF without overt coronary artery disease. Various reasons
have been proposed for the persistent hypertroponinemia,
such as increased wall stress, myocyte damage from in-
ﬂammatory cytokines and/or oxidative stress, neurohor-
monal activation, and coronary microvascular dysfunction.
These potential mechanisms enhance cardiac troponin
release through myocardial necrosis, apoptosis, and troponin
degradation.1,17 Therefore, it is rationale to speculate that
persistent hypertroponinemia may represent myocardial
necrosis and apoptosis in the absence of myocardial
infarction in patients with HF. Replacement or diffuse
reactive interstitial myocardial ﬁbrosis is an important his-
tological feature of various forms of cardiomyopathies and
contributes to the progression of HF.4,5,18 Replacement
myocardial ﬁbrosis is most commonly found in the setting
of ischemic scarring, which is caused by myocardial
infarction and subsequent myocardial necrosis, andcorresponds to the replacement of myocytes with myoﬁ-
broblasts after myocardial necrosis or apoptosis associated
with myocardial damage in HF.19 Diffuse reactive intersti-
tial ﬁbrosis is caused by neurohormonal activation, such as
activation of the renin-angiotensin aldosterone system,
oxidative stress, and hemodynamic impairment.20e22 These
mechanisms of reactive interstitial ﬁbrosis could also be
common to those involved in cardiac troponin release in HF.
Thus, the same mechanisms could also explain the positive
correlation between myocardial ﬁbrosis and cardiac
troponin release in patients with HF.
Circulating cardiac troponin level is inﬂuenced by
various factors such as renal clearance,23 skeletal muscle
disease,24 and presence of coronary artery disease.25 Renal
clearance and skeletal muscle disease might affect quite
poor correlation between circulating cTnT levels and
transcardiac cTnT release from heart (r ¼ 0.517). To
exclude the involvement of these factors, we evaluated
transcardiac cTnT release directly by calculating the dif-
ference in cTnT level measured in the CS and Ao in non-
ischemic patients with HF. Although such method is not
suitable for routine clinical evaluation, it nevertheless allows
precise evaluation of the relation between myocardial
damage, assessed by transcardiac cTnT release, and
myocardial ﬁbrosis. In this study, circulating cTnT levels
correlated positively with transcardiac cTnT release, and the
latter also correlated with the presence and extent of LGE.
These results suggest that high circulating cTnT level could
reﬂect ongoing myocardial damage in vulnerable myocar-
dium with ﬁbrotic change and progression of myocardial
ﬁbrosis, with potential worsening of prognosis in patients
with HF. Masson et al26 reported that serial changes in
circulating cTnT levels are associated with the severity and
progression of HF and are of robust prognostic value
beyond that of a single measurement. Similarly, progression
of myocardial ﬁbrosis, assessed by serial evaluation of LGE-
CMR, is a marker of future adverse events in patients with
hypertrophic cardiomyopathy.9 That serial measurement of
circulating cTnT level is more convenient and reproducible
method compared with serial evaluation with LGE-CMR,
which highlights the potential usefulness of this parameter
in daily clinical practice for the assessment of the presence
and severity of myocardial ﬁbrosis. Further studies are
needed to conﬁrm these conclusions.
Several ﬁbrosis-related biomarkers, such as procollagen
type III aminoterminal peptide (a marker of collagen turn-
over) and galectin-3 (a proﬁbrotic molecule), have been
reported to correlate with cardiac remodeling, increased risk
of future HF, and cardiovascular events.27,28 However, the
sources of these biomarkers are not limited to the heart.29
Ideally, one should assess the relation between myocardial
ﬁbrosis and transcardiac levels of these biomarkers, how-
ever; there are currently no suitable and sensitive commer-
cially available assay systems that can measure small
amounts of biomarkers released from the myocardium. In
contrast to the above molecules, cTnT is cardiac speciﬁc,
and its production by the myocardium and release into the
coronary circulation could be evaluated in patients with
HF.17 This is the most important advantages of measuring
cTnT compared with other ﬁbrosis-related biomarkers. Kop
et al11 reported that increases in hs-cTnT levels over time
Table 3
Results of univariate and multivariate logistic regression analyses for parameters of LGE-positive ﬁnding in study patients
Variables Univariate Analysis Multivariate Analysis
p Value OR (95% CI) p Value OR (95% CI)
Age (per yr) 0.65 1.01 (0.98e1.04) 0.81 1.01 (0.97e1.05)
Men (yes) 0.39 1.53 (0.58e4.00) 0.50 1.56 (0.43e5.65)
Body mass index (per kg/m2) 0.85 1.01 (0.91e1.13)
New York Heart Association functional class III (yes) 0.10 6.21 (0.72e52.63)
Hypertension (yes) 0.54 1.33 (0.53e3.36)
Dyslipidemia (yes) 0.84 1.10 (0.44e2.76)
Diabetes mellitus (yes) 0.61 0.72 (0.21e2.49)
Cardiac index (per L/min/m2) 0.89 1.05 (0.50e2.24)
PCWP (per mm Hg) 0.007 1.18 (1.05e1.33) 0.03 1.19 (1.02e1.40)
LVEDP (per mm Hg) 0.13 1.06 (0.98e1.14)
cTnT level in Ao >13.5 ng/L (yes) 0.006 4.33 (1.54e12.20) 0.11 2.92 (0.80e10.64)
(cTnT level in CS)  (cTnT level in Ao); available (yes) 0.002 28.05 (3.42e230.33) 0.006 25.00 (2.56e243.96)
BNP level in Ao (per 10 pg/ml) 0.04 1.04 (1.00e1.07)
(BNP level in CS)  (BNP level in Ao) (per 10 pg/ml) 0.005 1.04 (1.01e1.08) 0.15 1.03 (0.99e1.07)
Hemoglobin (per g/dl) 0.06 1.30 (0.99e1.70)
Estimated glomerular ﬁltration rate (per ml/min/1.73 m2) 0.99 0.99 (0.96e1.02)
Hemoglobin A1c (per %) 0.78 0.93 (0.56e1.53)
High-sensitivity C-reactive protein (per mg/dl) 0.60 1.55 (0.31e7.71)
Left ventricular ejection fraction (per %) 0.36 1.02 (0.98e1.06)
CI ¼ conﬁdence interval; LVEDP ¼ left ventricular end-diastolic pressure; OR ¼ odds ratio; PCWP ¼ pulmonary capillary wedge pressure.
Table 4
Results of univariate linear regression analyses for LGE volume and %LGE
Variable LGE Volume %LGE
r p Value r p Value
Age (yrs) 0.059 0.72 0.053 0.75
Body mass index 0.103 0.53 0.022 0.90
Cardiac index 0.163 0.32 0.102 0.54
PCWP 0.092 0.58 0.157 0.34
LVEDP 0.383 0.02 0.392 0.01
Left ventricular ejection fraction 0.195 0.23 0.143 0.39
Hemoglobin 0.013 0.94 0.021 0.90
Hemoglobin A1c 0.037 0.83 0.075 0.65
Estimated glomerular
ﬁltration rate
0.168 0.31 0.048 0.77
Log (high-sensitivity
C-reactive protein)
0.097 0.56 0.079 0.64
Log (cTnT level in Ao) 0.491 0.002 0.346 0.03
Log ([cTnT level in CS] 
[cTnT level in Ao])
0.460 0.003 0.356 0.03
Log (BNP level in Ao) 0.405 0.01 0.423 0.007
Log ([BNP level in CS] 
[BNP level in Ao])
0.282 0.08 0.327 0.04
LVEDP ¼ left ventricular end-diastolic pressure; PCWP ¼ pulmonary
capillary wedge pressure.
1702 The American Journal of Cardiology (www.ajconline.org)were related to higher levels of procollagen type III ami-
noterminal peptide at 3 years of follow-up in patients with
HF. These results, together with the present ﬁndings, sug-
gest that progression of myocardial ﬁbrosis seems to
correlate with ongoing myocardial damage and that this
process contributes to worsening HF.In this study, circulating BNP levels and left ventricular
end-diastolic pressure also correlated positively with the
extent of LGE. These results suggest that the extent of
myocardial ﬁbrosis is associated with impaired hemody-
namics, because BNP is released from the heart in response
to volume expansion and pressure overload associated with
wall stress in HF.30 Impaired hemodynamics and worsening
HF accompanied by neurohormonal activation and inﬂam-
mation cause the progression of myocardial ﬁbrosis, and
myocardial ﬁbrosis additionally worsens HF symptoms and
causes arrhythmogenesis.7e10,20e22 This vicious cycle is an
important clinical condition of worsening HF syndrome.
This study has some limitations. An important point
to consider with the study ﬁndings is that HF etiology could
be heterogeneous, and the mechanisms of cTnT release
might differ among cardiomyopathies. In addition, our
study investigated only a relatively small number of patients
from a single center and was limited to patients with non-
ischemic and well-compensated HF. CMR-LGE is consid-
ered as old and completed myocardial ﬁbrosis but not
ongoing ﬁbrosis. To minimize this point, we excluded the
patients with old myocardial infraction and ischemic HF.
The main limiting factor of quantitative analysis of
myocardial ﬁbrosis by CMR-LGE is that the ﬁbrotic process
is often diffuse in nonischemic cardiomyopathies, and the
extent of LGE could be underestimated in such patients due
to lack of the true normal nonﬁbrotic myocardium as a
reference. In addition, the optimum threshold for the detec-
tion of myocardial ﬁbrosis in different types of cardiomy-
opathies is currently undetermined in SD techniques. T1
mapping and full-width half maximum technique might
provide better and more accurate evaluation of diffuse
myocardial ﬁbrosis.
Figure 3. Correlation of Log (DcTnT [CS-Ao]) with LGE volume and %LGE. Log (DcTnT [CS-Ao]) levels correlated positively with LGE volume (A) and %
LGE (B).
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